EDAP Selects Leading Reimbursement Consultancies MTP and Argenta Advisors to Expand Market Access and Coverage of HIFU in the US

EDAP TMS, the global leader in robotic energy-based therapies, announces today that the company has selected Medical Technology Partners (MTP) and Argenta Advisors, two leading reimbursement consultancies, to further expand coverage, accelerate market access and secure future payment rates for the company’s Focal One high intensity focused ultrasound (HIFU) procedure in the US. The announcement follows the establishment of a Category 1 CPT code, and physician reimbursement for HIFU, that went into effect on January 1, 2021. Read more

The Future Is Now: Marc Oczachowski of EDAP TMS On How Their Technological Innovation Will Shake Up Healthcare

Marc Oczachowski is Chairman of the Board and Chief Executive Officer of EDAP TMS, a high-tech medical company which develops, manufactures markets minimally invasive therapeutic ultrasound solutions for urology, tumor removal, localized prostate cancer, and infectious diseases. Read more

Positive 24 month interim results of French Urology Association (AFU) sponsored clinical trial study comparing HIFU to radical prostate surgery

Positive 24 month interim results of French Urology Association (AFU) sponsored clinical trial study comparing HIFU to radical prostate surgery: results on 3,329 patients demonstrate significant difference in efficacy in favor of HIFU versus Radical Prostatectomy (RP). Read more

By bringing a safe, ambulatory and non-invasive solution to patients with #prostate conditions, watch how EDAP TMS and #HIFU users are handling the situation with COVID-19 when elective procedures are currently being put on-hold.

EDAP TMS and #HIFU users are handling the situation with COVID-19 when elective procedures are currently being put on-hold. Read more

Final US 2021 reimbursement rules for High Intensity Focused Ultrasound (HIFU)

U.S. Centers for Medicare and Medicaid Services (CMS) has issued its final rules establishing, for the first time, a Category 1 CPT code which facilitates reimbursement for the ablation of malignant prostate tissue with HIFU technology, effective January 1, 2021. Read more

First patients treated in phase 2 study of Focal One for the treatment of deep invasive endometriosis

the first two patients have been treated in the company’s Phase 2 clinical trial assessing Focal One® High Intensity Focused Ultrasound (HIFU) as a potential treatment for deep rectal endometriosis. A total of 38 women will be enrolled in the study and treated at five major hospitals and assessed over a six-month follow-up period. Read more

Approval received for phase II study evaluating HIFU for deep invasive endometriosis

EDAP TMS has received approval from French health authorities to initiate a Phase II multicenter clinical trial evaluating its Focal One® HIFU to treat deep rectal endometriosis. Read more

Two publications highlighting favorable HIFU focal therapy outcomes in journal of urology

Studies conducted at the University of Southern California and University of Miami represent the first U.S. publications detailing successful partial-gland ablation using high intensity focused ultrasound therapy to treat prostate cancer patients since FDA cleared the technology in 2015. Read more

Two publications highlighting favorable HIFU focal therapy outcomes in journal of urology

Studies conducted at the University of Southern California and University of Miami represent the first U.S. publications detailing successful partial-gland ablation using high intensity focused ultrasound therapy to treat prostate cancer patients since FDA cleared the technology in 2015. Read more

EDAP Announces Recent Focal One Sales Successes

Company completes four Focal One sales, including three bundled sales that combine Focal One® with Exact Imaging’s ExactVu micro ultrasound imaging solution.

Read more